med.stanford.edu

Share

med.stanford.edu

 •  December 13, 2017

When the Food and Drug Administration approved the first drug for people with spinal muscular atrophy a year ago, clinicians finally had hope for improving the lives of patients with the rare debilitating muscular disease. But the extraordinary cost of the drug and complicated logistics of delivering it present barriers for many patients, according...

med.stanford.edu

 •  December 7, 2017

2017 Pharmaceutical companies have come under fire in recent years for failing to meet standards for reporting the results of clinical trials, but a new analysis by the nonprofit organization Bioethics International indicates that some companies are improving. On Dec. 5, Bioethics International published its second “Good Pharma Scorecard,” which...

med.stanford.edu

 •  May 10, 2017

Tracey Campbell has lived for seven years with lymphedema, a chronic condition that causes unsightly swelling in her left leg. The disease, which stems from a damaged lymphatic system, can lead to infections, disfigurement, debilitating pain and disability. There is no cure. The only available treatment is to wear compression garments or use...